Stocks
Arcutis Biotherapeutics Financial Statements (ARQT) |
||||||||||
| Arcutis Biotherapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.05.2023 | 08.08.2023 | 03.11.2023 | 27.02.2024 | 14.05.2024 | 14.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 2.78 | 5.19 | 38.1 | 13.5 | 49.6 | 106.4 | |||
| Operating Income, bln rub | -76.3 | -66.8 | -36.9 | -61.2 | -31.6 | -196.5 | ||||
| EBITDA, bln rub | ? | -73.1 | -63.6 | -34.2 | -60.8 | -31.3 | -189.9 | |||
| Net profit, bln rub | ? | -79.7 | -71.0 | -44.8 | -66.3 | -35.4 | -217.4 | |||
| OCF, bln rub | ? | -80.3 | -66.5 | -44.0 | -56.2 | -31.6 | -198.3 | |||
| CAPEX, bln rub | ? | 0.082 | 0.276 | 0.064 | 0.006 | 0.000 | 0.346 | |||
| FCF, bln rub | ? | -80.4 | -66.8 | -44.0 | -56.3 | -31.6 | -198.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 78.3 | 71.2 | 73.8 | 72.3 | 77.9 | 295.2 | ||||
| Cost of production, bln rub | 0.783 | 0.776 | 1.18 | 2.44 | 3.26 | 7.66 | ||||
| R&D, bln rub | 35.3 | 25.2 | 26.2 | 23.8 | 23.1 | 98.4 | ||||
| Interest expenses, bln rub | 7.04 | 7.35 | 7.56 | 7.76 | 7.48 | 30.2 | ||||
| Assets, bln rub | 379.5 | 320.7 | 293.0 | 341.4 | 478.5 | 478.5 | ||||
| Net Assets, bln rub | ? | 139.7 | 80.5 | 46.7 | 88.7 | 224.9 | 224.9 | |||
| Debt, bln rub | 203.4 | 204.2 | 205.1 | 205.9 | 206.7 | 206.7 | ||||
| Cash, bln rub | 332.4 | 268.7 | 227.1 | 272.8 | 404.5 | 404.5 | ||||
| Net debt, bln rub | -129.0 | -64.5 | -22.0 | -66.9 | -197.7 | -197.7 | ||||
| Ordinary share price, rub | 11.0 | 9.53 | 5.31 | 3.23 | 9.91 | 2.21 | ||||
| Number of ordinary shares, mln | 61.2 | 61.4 | 61.7 | 92.6 | 111.0 | 111.0 | ||||
| Market cap, bln rub | 673 | 585 | 328 | 299 | 1 100 | 245 | ||||
| EV, bln rub | ? | 544 | 521 | 306 | 232 | 903 | 48 | |||
| Book value, bln rub | 133 | 74 | 40 | 82 | 219 | 219 | ||||
| EPS, rub | ? | -1.30 | -1.16 | -0.73 | -0.72 | -0.32 | -1.96 | |||
| FCF/share, rub | -1.31 | -1.09 | -0.71 | -0.61 | -0.28 | -1.79 | ||||
| BV/share, rub | 2.17 | 1.20 | 0.65 | 0.89 | 1.97 | 1.97 | ||||
| EBITDA margin, % | ? | -2 627% | -1 226% | -89.7% | -449.4% | -63.1% | -178.5% | |||
| Net margin, % | ? | -2 867% | -1 368% | -117.5% | -490.0% | -71.4% | -204.4% | |||
| FCF yield, % | ? | -45.2% | -52.8% | -80.1% | -82.8% | -18.1% | -80.9% | |||
| ROE, % | ? | -239.7% | -418.6% | -580.3% | -295.2% | -96.7% | -96.7% | |||
| ROA, % | ? | -88.3% | -105.1% | -92.5% | -76.7% | -45.4% | -45.4% | |||
| P/E | ? | -2.01 | -1.74 | -1.21 | -1.14 | -5.06 | -1.13 | |||
| P/FCF | -2.21 | -1.89 | -1.25 | -1.21 | -5.54 | -1.24 | ||||
| P/S | ? | 104.0 | 50.2 | 6.68 | 5.02 | 10.3 | 2.31 | |||
| P/BV | ? | 5.07 | 7.94 | 8.18 | 3.64 | 5.03 | 1.12 | |||
| EV/EBITDA | ? | -1.78 | -1.71 | -1.30 | -1.00 | -4.75 | -0.25 | |||
| Debt/EBITDA | 0.42 | 0.21 | 0.09 | 0.29 | 1.04 | 1.04 | ||||
| R&D/CAPEX, % | 43 104% | 9 137% | 40 994% | 396 250% | 28 431% | |||||
| CAPEX/Revenue, % | 2.95% | 5.32% | 0.17% | 0.04% | 0.00% | 0.33% | ||||
| Arcutis Biotherapeutics shareholders | ||||||||||
